Skip to main content

Table 2 Plasma total fatty acid profiles by GC

From: Diabetic encephalopathy: beneficial effects of supplementation with fatty acids ω3 and nordihydroguaiaretic acid in a spontaneous diabetes rat model

Experimental groups

 

Control eSS

ω6

ω6 + NDGA

ω3

ω3 + NDGA

Wistar

Fatty acids

 SFA

23,56#

±2,28

45,89#*

±3,46

38,20#*

±3,18

22,20#*

±0,34

25,00#*

±2,90

27,90*

±2,53

 MUFAs

27,60#

±2,60

17,46#*

±1,51

24,50#*

±1,29

33,30*

±0,25

45,40#

±0,76

22,50*

±1,36

 PUFAs ω6

38,20

±3,65

30,37#*

±0,10

23,70#*

±1,09

29,00*

±0,04

12,00*

±0,44

38,00*

±3,18

 PUFAs ω3

4,00#

±0,54

1,83

±0,01

6,20

±0,33

15,10

±0,16

19,30#

±0,48

16,40*

±0,36

 PUFAs Total

42,20

±2,09

32,20#

±0,05

29,10#

±0,71

44,00

±0,10

31,10#

±0,46

54,30*

±1,77

 Ratio ω6/ω3

9,55#

16,60#

3,82#*

1,92*

0,62*

2,32*

  1. Profiles was determined at 12TH month of age in experimental groups
  2. #Indicate significant difference to Wistar, p ≤ 0.05. *Indicate significant difference to Control eSS, p ≤ 0.05
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X